Treatment Information

Back

Lung Cancer treatment details. Chemotherapy.

Oncologisch Centrum, Brussels, Belgium.

Survival: monthsCountry:Belgium
Toxiciy Grade:4City/State/Province:Brussels
Treatments:ChemotherapyHospital:Oncologisch Centrum
Drugs:Journal:Link
Date:Mar 2007

Description:

Patients: This phase II study involved 48 patients with advanced unresectable non-small cell lung cancer. The median age was 65, ranging from 39-78 years. Most of the patients were men (77%). None had prior radiotherapy or chemotherapy.

Treatment: Patients were treated with the chemotherapy drugs paclitaxel, carboplatin, and gemcitabine. After completing the chemotherapy, they underwent radiation therapy.

Toxicity: Two grade 4 toxicities associated with the treatment were reported: infection and haemoptysis. Grade 3/4 hematological toxicities affecting leukocytes, thrombocytes, neutrophils, and hemoglobin were also reported. Three patients died from causes not related to treatment.

Results: The median overall survival was 15.7 months. The median time to progression was 10.1 months.

Support: These studies were supported in part by grants from E. Lilly and Bristol-Meyers Squibb, which make and market drugs used in this study. These drugs were provided at no cost from these companies.

Correspondence: Dr. Jacques De Greve



Back